[go: up one dir, main page]

PE20080704A1 - Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo - Google Patents

Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo

Info

Publication number
PE20080704A1
PE20080704A1 PE2007000614A PE2007000614A PE20080704A1 PE 20080704 A1 PE20080704 A1 PE 20080704A1 PE 2007000614 A PE2007000614 A PE 2007000614A PE 2007000614 A PE2007000614 A PE 2007000614A PE 20080704 A1 PE20080704 A1 PE 20080704A1
Authority
PE
Peru
Prior art keywords
alkyl
cyclopropyl
indolobenzazepine
fused
hepatitis
Prior art date
Application number
PE2007000614A
Other languages
English (en)
Inventor
Robert G Gentles
Piyasena Hewawasam
Min Ding
Carl P Bergstrom
Scott W Martin
Kap-Sun Yeung
Thomas W Hudyma
Xiaofan Zheng
John A Bender
John F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20080704A1 publication Critical patent/PE20080704A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS INDOLOBENZAZEPINA FUSIONADOS A CICLOPROPILO DE FORMULA (I), EN DONDE R1 ES CO2R5 O CONR6R7; R2 ES PIPERIDINILO O PIPERAZINILO SUSTITUIDO CON 3 SUSTUSTITUYENTES SELECCIONADOS DE ALQUILO, ALCOXIALQUILO, ENTRE OTROS; R3 ES H, HALO, ALQUILO, ALQUENILO, ALCOXI, ENTRE OTROS; R4 ES CICLOALQUILO; R5 ES H O ALQUILO; R6 ES H, ALQUILO, ALQUILO-SO2; CICLOALQUILO-SO2, (R7)(R8)NSO2 O (R9)SO2; R7 Y R8 SON INDEPENDIENTEMENTE H O ALQUILO. SON SELECCIONADOS: CICLOPROPIL[d]INDOLO[2,1-a][2]BENZAZEPINA-5-CARBOXAMIDA,1a-[[(3a,5a)-4-ACETIL-3,5-DIMETIL-1-PIPERAZINIL]CARBONIL]-8-CICLOHEXIL-N-[(DIMETILAMINO)SULFONIL]-1,1a,2,12b-TETRAHIDRO-11-METOXI, CICLOPROPIL[d]INDOLO[2,1-a][2]BENZAZEPINA-5-CARBOXAMIDA, 8-CICLOHEXIL-1,1a,2,12b-TETRAHIDRO-11-METOXI-N-(2-PROPILSULFONIL}-1a-[[(3R,5S)-3,4,5-TRIMETIL-1-PIPERAZINIL]CARBONIL], ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDE COMPRENDER OTRO AGENTE ANTI VHC. ESTOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE NS5B DEL VHC SIENDO UTILES EN EL TRATAMIENTO DE INFECCION DEL VHC
PE2007000614A 2006-05-22 2007-05-18 Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo PE20080704A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80236806P 2006-05-22 2006-05-22
US89425307P 2007-03-12 2007-03-12

Publications (1)

Publication Number Publication Date
PE20080704A1 true PE20080704A1 (es) 2008-06-13

Family

ID=38514150

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000614A PE20080704A1 (es) 2006-05-22 2007-05-18 Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo

Country Status (5)

Country Link
US (1) US7521441B2 (es)
AR (1) AR061053A1 (es)
PE (1) PE20080704A1 (es)
TW (1) TW200817403A (es)
WO (1) WO2007140109A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688420A4 (en) * 2003-11-19 2008-10-22 Japan Tobacco Inc 5-5 LOW-CONDENSED HETEROCYCLIC COMPOUND AND THEIR USE AS HCV POLYMERASE INHIBITOR
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
AU2008339917B2 (en) 2007-12-24 2013-02-07 Tibotec Pharmaceuticals Macrocyclic indoles as hepatitis C virus inhibitors
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8178523B2 (en) * 2008-03-27 2012-05-15 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2280978B1 (en) * 2008-03-27 2013-04-24 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TWI454476B (zh) 2008-07-08 2014-10-01 Tibotec Pharm Ltd 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
BR112012032889A2 (pt) 2010-06-24 2015-09-15 Janssen R & D Ireland preparação do ácido 13-ciclo-hexil-3-metóxi-6-[metil-(2-{2-[metil-(sulfamoil)-amino]-etóxi}-etil)-carbamoil]-7h-indol-[2,1-a]-[2]-benzazepina-10-carboxílico
EP2655362A1 (en) 2010-12-22 2013-10-30 Abbvie Inc. Hepatitis c inhibitors and uses thereof
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
EP2658858A4 (en) 2010-12-30 2014-06-25 Enanta Pharm Inc MACROCYCLIC INHIBITORS OF HEPATITIS C SERINE PROTEASE PHENANTHRIDINE
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2018009811A1 (en) 2016-07-08 2018-01-11 Genentech, Inc. Use of human epididymis protein 4 (he4) for assessing responsiveness of muc 16-positive cancer treatment
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005013922D1 (de) 2004-02-24 2009-05-28 Japan Tobacco Inc Kondensierte heterotetracyclische verbindungen und deren verwendung als hcv-polymerase-inhibitor
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
WO2006040039A1 (de) 2004-10-13 2006-04-20 Merck Patent Gmbh Als kinaseinhibitoren geeignete derivate des n, n ´ -diphenylharnstoffs
AU2005298403A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Also Published As

Publication number Publication date
TW200817403A (en) 2008-04-16
US7521441B2 (en) 2009-04-21
AR061053A1 (es) 2008-07-30
WO2007140109A1 (en) 2007-12-06
US20070270406A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
PE20080704A1 (es) Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
PE20080070A1 (es) Derivados de indolobenzazepina fusionados a ciclopropilo como inhibidores de la polimerasa ns5b del virus de la hepatitis c
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
CL2011002016A1 (es) Compuestos derivados de benzimidazol con actividad inhibidora de la funcion de la proteina ns5a codificada por el virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; utiles en el tratamiento de una infeccion por el virus de la hepatitis c (vhc).
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
SG161315A1 (en) Compounds and methods for the treatment or prevention of flavivirus infections
PE20040836A1 (es) Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc)
PE20240775A1 (es) Compuestos antivirales
AR042583A1 (es) Macrolidos
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
UY27503A1 (es) Nuevos derivados de piperazina
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
AR040047A1 (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6
PE20070983A1 (es) COMPUESTOS DERIVADOS DE 3-DESAZAPURINA COMO AGONISTAS DEL RECEPTOR Toll-LIKE (TLR7)
PE20000949A1 (es) Tripeptidos inhibidores de la hepatitis c
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
CY1107200T1 (el) Ενωσεις αναστολης της ηπατιτιδας c
MX2007004979A (es) Derivados de indol tetraciclicos como agentes antiviricos.
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
BR112013007696A2 (pt) composto, composição farmacêutica, usos do referido composto e da referida composição
CY1110437T1 (el) Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c
BRPI0412659A (pt) isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto

Legal Events

Date Code Title Description
FC Refusal